



OXA-484, an OXA-48-Type Carbapenem-Hydrolyzing Class D β -Lactamase From *Escherichia coli*

Julian Sommer¹, Kristina M. Gerbracht¹, Felix F. Krause¹, Florian Wild¹, Manuela Tietgen^{1,2,3}, Sara Riedel-Christ¹, Janko Sattler⁴, Axel Hamprecht^{4,5}, Volkhard A. J. Kempf^{1,3} and Stephan Göttig^{1*}

¹ Institute for Medical Microbiology and Infection Control, University Hospital, Goethe University Frankfurt am Main, Frankfurt, Germany, ² Faculty of Biological Sciences of the Goethe University Frankfurt am Main, Frankfurt, Germany, ³ University Center of Competence for Infection Control of the State of Hesse, Frankfurt, Germany, ⁴ Institute for Medical Microbiology, Immunology and Hygiene, German Center for Infection Research (DZIF Partner Site Cologne-Bonn), University Hospital of Cologne, Cologne, Germany, ⁵ Institute for Medical Microbiology, University Hospital of Oldenburg, Oldenburg, Germany

OPEN ACCESS

Edited by:

Karsten Becker,
University Medicine Greifswald,
Germany

Reviewed by:

Costas C. Papagiannitsis,
University of Thessaly, Greece
Marco Maria D'Andrea,
University of Rome Tor Vergata, Italy

*Correspondence:

Stephan Göttig
Stephan.Goettig@kgu.de

Specialty section:

This article was submitted to
Antimicrobials, Resistance
and Chemotherapy,
a section of the journal
Frontiers in Microbiology

Received: 28 January 2021

Accepted: 14 April 2021

Published: 12 May 2021

Citation:

Sommer J, Gerbracht KM, Krause FF, Wild F, Tietgen M, Riedel-Christ S, Sattler J, Hamprecht A, Kempf VAJ and Göttig S (2021) OXA-484, an OXA-48-Type Carbapenem-Hydrolyzing Class D β -Lactamase From *Escherichia coli*. *Front. Microbiol.* 12:660094. doi: 10.3389/fmicb.2021.660094

OXA-48-like carbapenemases are among the most frequent carbapenemases in Gram-negative *Enterobacterales* worldwide with the highest prevalence in the Middle East, North Africa and Europe. Here, we investigated the so far uncharacterized carbapenemase OXA-484 from a clinical *E. coli* isolate belonging to the high-risk clone ST410 regarding antibiotic resistance pattern, horizontal gene transfer (HGT) and genetic support. OXA-484 differs by the amino acid substitution 214G compared to the most closely related variants OXA-181 (214R) and OXA-232 (214S). The *bla*_{OXA-484} was carried on a self-transmissible 51.5 kb IncX3 plasmid (pOXA-484) showing high sequence similarity with plasmids harboring *bla*_{OXA-181}. Intraspecies and intergenus HGT of pOXA-484 to different recipients occurred at low frequencies of 1.4×10^{-7} to 2.1×10^{-6} . OXA-484 increased MICs of temocillin and carbapenems similar to OXA-232 and OXA-244, but lower compared with OXA-48 and OXA-181. Hence, OXA-484 combines properties of OXA-181-like plasmid support and transferability as well as β -lactamase activity of OXA-232.

Keywords: OXA-48, OXA-484, IncX, carbapenemases, beta-lactamases, *Enterobacterales*, plasmid

INTRODUCTION

Carbapenem resistance in *Enterobacterales* has dramatically increased worldwide in recent years and poses a major threat to public health. Antibiotic treatment options for infections caused by carbapenem-resistant *Enterobacterales* (CPE) are severely limited, with often very few or even no antibiotic agents remaining effective. Resistance to carbapenems is primarily caused by carbapenemases, i.e., bacterial enzymes that hydrolyze carbapenems and most other β -lactam antibiotics. OXA-48 is one of the most prevalent carbapenemases worldwide with the highest prevalence in the Middle East, North Africa and Europe (Cantón et al., 2012). OXA-48 enzymes lead to carbapenem resistance and are most often found in *Escherichia coli* and *Klebsiella pneumoniae* (Pitout et al., 2019).

The rapid dissemination of OXA-48 has been attributed to efficient horizontal gene transfer (HGT) of plasmids harboring *bla*_{OXA-48} and a low fitness burden by carriage of these plasmids

(Hamprecht et al., 2019). At least 35 variants of OXA-48, commonly referred to as OXA-48-like β -lactamases (e.g., OXA-181, OXA-232, OXA-244), have been reported (Naas et al., 2017). Even though these variants differ only by single or few amino acid substitutions, a high degree of diversity is observed regarding the β -lactam hydrolysis pattern, genetic support of OXA-48-like encoding genes and HGT (Potron et al., 2011, 2013). The gene encoding OXA-48, *bla*_{OXA-48}, is mostly present on an epidemic 63.6 kb IncL plasmid and bracketed by two identical insertion sequences (IS), IS1999, forming the composite transposon Tn1999 (Poirel et al., 2012). In contrast, *bla*_{OXA-181} is primarily found on a 51.5 kb IncX3 plasmid and has been associated with *ISEcp1* in a Tn2013 transposon structure, whereas *bla*_{OXA-232} is commonly located on a non-conjugative 6.1 kb ColE-type plasmid (Qin et al., 2018; Li et al., 2019). In case of *bla*_{OXA-244}, the gene is mostly identified on the chromosome of *E. coli* and has been increasingly identified in the European Union in recent years (European Centre for Disease Prevention and Control, 2020; Kremer et al., 2020; Chudejova et al., 2021).

OXA-484, a variant of the OXA-48-like family, has been previously reported from a collection of OXA-48-like carbapenemase in the United Kingdom, but so far only the sequence is known (Findlay et al., 2017). Here we report on the genetic background, antibiotic resistance phenotype and HGT of this carbapenemase.

MATERIALS AND METHODS

Bacterial Isolates and Antimicrobial Susceptibility Testing

Enterobacteriales clinical isolates carrying the plasmid-borne OXA-48-like carbapenemases OXA-48, OXA-181, OXA-232, OXA-244, and OXA-484 were recovered from patients of the University Hospital Frankfurt, Germany (Table 1). All isolates were phenotypically characterized and tested for *bla*_{OXA-48-like} by PCR and Sanger sequencing as previously described (Göttig et al., 2015). Antimicrobial susceptibility was determined using antibiotic gradient strips (Liofilchem, Roseto degli Abruzzi, Italy), broth micro dilution for colistin and agar dilution for fosfomycin as recommended by EUCAST. Minimal inhibitory concentrations (MIC) were interpreted according to EUCAST guidelines v10.0. For detection of carbapenemases, chromID® CARBA SMART plates (bioMérieux, Nürtingen, Germany) and the immunochromatographic CARBA 5 lateral flow test (NG-Biotech, Guipry, France) were used (Baeza et al., 2019; Göttig et al., 2020).

Cloning of *bla*_{OXA-48-like}

The open reading frames of *bla*_{OXA-484}, *bla*_{OXA-244}, *bla*_{OXA-232}, *bla*_{OXA-181}, and *bla*_{OXA-48}, including their native promoters, were amplified using the primers OXA-TOPO-F1, OXA-244-TOPO-F1, OXA-48-TOPO-F1, and preOXA-48B (Supplementary Table 1) and cloned into the expression vector pCR-Blunt II-TOPO (Invitrogen, Darmstadt, Germany) as described before (Potron et al., 2011). The resulting

vectors pTOPO_OXA-484, pTOPO_OXA-244, pTOPO_OXA-232, pTOPO_OXA-181, and pTOPO_OXA-48 were used to transform electrocompetent *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ (Choi et al., 2006).

Horizontal Gene Transfer of *bla*_{OXA-48-like} Harboring Plasmids

Transconjugation of *bla*_{OXA-48-like} harboring plasmids was conducted by liquid mating as previously described (Gruber et al., 2014). Briefly, a mixture of donors and recipients in brain heart infusion broth were incubated over night at 37°C and subsequently plated on chromogenic agar plates containing 100 mg/L sodium azide and 10 mg/L amoxicillin-clavulanic acid to select for transconjugants (Tc). Clinical *E. coli* and *K. pneumoniae* isolates encoding *bla*_{OXA-48}, *bla*_{OXA-181}, *bla*_{OXA-232}, or *bla*_{OXA-484} were employed as donors and sodium azide-resistant *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ as recipients (Hamprecht et al., 2019). Plasmid DNA from clinical isolates carrying *bla*_{OXA-232} was extracted using the PureYield™ Plasmid Midiprep System (Promega, Walldorf, Germany). Transformation of J53 and PRZ using *bla*_{OXA-232} encoding plasmids was done by electroporation and transformants (Tf) were selected as described above. Presence of OXA-48-like carbapenemases in Tc and Tf was verified by disk diffusion antibiotic testing and the CARBA 5 lateral flow test. All *E. coli* J53 Tc were analyzed using long-read genome sequencing and disk diffusion testing as recommended by EUCAST. Transconjugation frequency was determined by dividing the numbers of Tc colonies by the number of acceptor colonies.

Whole Genome Sequencing

Whole genome sequencing was carried out for all clinical isolates using short-read technology (MiSeq or NovaSeq platform, Illumina, San Diego, United States) and long-read technology (MinION platform, Oxford Nanopore Technologies, Oxford, United Kingdom). DNA was extracted from isolates using the DNeasy UltraClean Microbial Kit (Qiagen, Hilden, Germany). For Illumina sequencing, a v3 reagent kit was applied generating either 150 or 250 bp paired-end reads. Library preparation for Nanopore sequencing was done using the SQK-RBK004 rapid barcoding kit. Sequencing was performed on a MinION MK1B sequencer utilizing a R9.4.1 flow cell. Raw signal data was base called and demultiplexed using the high accuracy base calling model of guppy basecaller version 4.0.11.

Bioinformatic Analysis

Raw data was filtered using trimmomatic for short reads and NanoFilt for long reads resulting in datasets of reads with an average genome coverage of at least 100-fold for short-reads and at least 30-fold for long-reads (Bolger et al., 2014; de Coster et al., 2018). *De novo* hybrid assembly was conducted using Unicycler version 0.4.8 utilizing the bold assembly mode (Wick et al., 2017). The obtained assemblies were annotated using Prokka version 1.14.6 (Seemann, 2014). Sequence types were determined using

TABLE 1 | Characteristics of clinical isolates harboring OXA-48-like carbapenemases and recipient strains *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ.

Isolate	Species	OXA-48-like	ST ^a	Plasmid size (kb)	Inc ^b	References
EC-JS316	<i>E. coli</i>	OXA-484	410	51.5	IncX3	This study
EC-2700	<i>E. coli</i>	OXA-48	354	61.1	IncL	Hamprecht et al., 2019
EC-JS426	<i>E. coli</i>	OXA-48	448	63.6	IncL	This study
KP-1402	<i>K. pneumoniae</i>	OXA-48	16	63.6	IncL	This study
KP-1673	<i>K. pneumoniae</i>	OXA-48	101	63.6	IncL	Hamprecht et al., 2019
KP-4113	<i>K. pneumoniae</i>	OXA-232	231	6.1	ColE	This study
KP-4814	<i>K. pneumoniae</i>	OXA-232	2096	6.1	ColE	This study
EC-5255	<i>E. coli</i>	OXA-181	3268	51.5	IncX3	This study
EC-2800	<i>E. coli</i>	OXA-181	940	51.5	IncX3	This study
KP-4313	<i>K. pneumoniae</i> ^c	OXA-181	5040	50.2	IncX3	This study
KP-SC771	<i>K. pneumoniae</i>	OXA-181	307	51.5	IncX3	This study
EC-SC1140	<i>E. coli</i>	OXA-244	38	–	–	This study
J53	<i>E. coli</i>	–	10	–	–	Gruber et al., 2014
PRZ	<i>K. pneumoniae</i> ^d	–	5208	–	–	Gruber et al., 2014

^aMLST according to Oxford scheme for *E. coli* and Pasteur scheme for *K. pneumoniae*. ^bPlasmid support of *bla*_{OXA-48-like}. ^c*K. quasipneumoniae* subsp. *similipneumoniae*. ^d*K. quasipneumoniae* subsp. *quasipneumoniae*.

the software mlst¹ v2.19.0 (Carattoli et al., 2014). ABRicate² v1.0.1 was applied using the databases PlasmidFinder and NCBI AMRFinderPlus for identification of plasmid incompatibility groups and antibiotic resistance genes, respectively, using thresholds of 100% gene coverage and ≥98% nucleotide sequence identity (Feldgarden et al., 2019). ISfinder was employed for annotation of insertion sequences (Siguier et al., 2006). Plasmid sequences were aligned using MAFFT 1.4.0 and visualized using Geneious³ 11.1.5 (Kato and Standley, 2013).

Statistical Analysis

For the comparison of transconjugation frequencies, continuous variables were assessed by Mann-Whitney *U* test. A *P*-value of < 0.05 was considered significant.

RESULTS

Identification of a Clinical Isolate Harboring *bla*_{OXA-484}

The *E. coli* isolate JS316 (EC-JS316) was obtained from a rectal swab of a patient admitted to the University Hospital Frankfurt in Germany. The patient was hospitalized due to acute dengue fever following a stay in India. The isolate EC-JS316 showed resistance to ertapenem with a MIC of 1 mg/L but was susceptible to imipenem (MIC 0.25 mg/L) and meropenem (MIC 0.125 mg/L) (Table 2). Furthermore, the isolate was resistant to piperacillin-tazobactam, cefotaxime, fluoroquinolones, gentamicin, tobramycin and trimethoprim-sulfamethoxazole, but remained susceptible to amikacin, fosfomycin, tigecycline and colistin (Supplementary Table 2). Strikingly, the isolate

EC-JS316 did not grow on chromID[®] CARBA SMART screening agar plates used for detection of CPE.

The CARBA 5 lateral flow test revealed the presence of an OXA-48-like β-lactamase. PCR and subsequent Sanger sequencing of the *bla*_{OXA-48-like} open reading frame identified *bla*_{OXA-484} (accession no. NG_049766.1). The gene *bla*_{OXA-484} has a single nucleotide substitution at position 640 (A→G) compared to the most closely related gene *bla*_{OXA-181} and two substitutions at position 639 (A→G) and 641 (T→A) compared to *bla*_{OXA-232}. These substitutions result in different amino acids at position 214 which is essential for enzyme activity: 214G for OXA-484, 214R for OXA-181, and 214S for OXA-232. The amino acid change R214S is also present in OXA-244 (Supplementary Figure 1).

Genome Analysis of *E. coli* EC-JS316

The genome of EC-JS316 was sequenced and assembled using a combined short- and long-read sequencing approach, resulting in the nucleotide sequences of a circular chromosome and five circular plasmids (Supplementary Table 3). The chromosome had a size of 4,718,403 bp coding for 4,398 predicted proteins and a GC-content of 50.8%. The ST of EC-JS316 was 410, which has been associated with international high-risk clones and acquisition of ESBL as well as different carbapenemases including OXA-181 (Roer et al., 2018; Patiño-Navarrete et al., 2020).

The resistome of EC-JS316 comprised the β-lactamase genes *bla*_{OXA-484}, *bla*_{TEM-1}, and *bla*_{EC-15}. *Bla*_{OXA-484} was localized together with the fluoroquinolone resistance gene *qnrS1* on the IncX3 plasmid pOXA-484 with a size of 51,480 bp (Figure 1). Additional antibiotic resistance genes were localized on the chromosome (*bla*_{EC-15}), on a 67 kb IncF plasmid and a non-typeable 9 kb plasmid, conferring resistance to trimethoprim-sulfamethoxazole (*dfrA17*, *sul2*), aminoglycosides [*aph*(6)-Id, *aac*(3)-IId, *aadA5*], tetracyclines [*tet*(B)], and macrolides [*mph*(A)] (Supplementary Table 3).

¹<https://github.com/tseemann/mlst>

²<https://github.com/tseemann/abricate>

³<https://geneious.com>

TABLE 2 | MICs of the clinical isolate EC-JS316 and transformants (Tf) or transconjugants (Tc) of the recipients *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ harboring plasmids encoding *bla*_{OXA-484}, *bla*_{OXA-181}, *bla*_{OXA-232}, and *bla*_{OXA-48}.

β-Lactam ^{a,b,c}	MIC (mg/L)										
	EC-JS316	J53	Tc pOXA-484 J53 ¹	Tf pOXA-232 J53 ²	Tc pOXA-181 J53 ³	Tc pOXA-48 J53 ⁴	PRZ	Tc pOXA-484 PRZ ¹	Tf pOXA-232 PRZ ²	Tc pOXA-181 PRZ ³	Tc pOXA-48 PRZ ⁴
Ampicillin	>256	2	>256	>256	>256	>256	64	>256	>256	>256	>256
Amoxicillin+CLA	128	2	>256	>256	>256	>256	2	>256	>256	>256	>256
Ampicillin+SUL	>256	2	>256	>256	>256	>256	8	>256	>256	>256	>256
Piperacillin	>256	2	>256	>256	32	64	8	>256	>256	>256	>256
Piperacillin+TAZ	>256	1	128	>256	32	64	8	256	>256	>256	>256
Ticarcillin+CLA	>256	4	>256	>256	>256	>256	16	>256	>256	>256	>256
Cephalothin	>256	8	16	16	16	16	4	16	32	16	16
Cefuroxime	>256	4	8	8	8	8	4	4	8	4	8
Cefoxitin	64	4	4	4	4	4	4	4	4	4	4
Cefotaxime	4	0.06	0.12	0.25	0.25	0.25	0.06	0.25	0.5	0.5	0.5
Ceftazidime	2	0.06	0.25	0.25	0.25	0.12	0.03	0.25	0.5	0.25	0.25
Temocillin	128	4	32	64	256	256	2	32	64	256	256
Ertapenem	1	0.03	0.12	0.12	0.12	0.25	0.01	1	2	2	2
Imipenem	0.25	0.25	0.5	0.5	1	1	0.12	0.5	0.5	1	1
Meropenem	0.12	0.03	0.06	0.06	0.12	0.12	0.03	0.12	0.12	0.25	0.25
Doripenem	0.06	0.01	0.06	0.06	0.12	0.12	0.03	0.06	0.12	0.12	0.12
Aztreonam	1	0.03	0.06	0.06	0.03	0.03	0.01	0.06	0.06	0.03	0.03

^aCLA, clavulanic acid (2 mg/L). ^bSUL, sulbactam (4 mg/L). ^cTAZ, tazobactam (4 mg/L). pOXA-48-like plasmid donors: ¹EC-JS316, ²KP-4814, ³EC-2800, ⁴EC-2700. MICs of Tc and Tf with at least 2-fold differences compared to OXA-484 are highlighted in bold.




FIGURE 1 | Plasmid map of pOXA-484 harboring *bla*_{OXA-484}. Colored arrows indicate antibiotic resistance genes *bla*_{OXA-484} (dark red) and *qnrS1* (light red), insertion elements (yellow), disrupted genes (gray), replication, partitioning, plasmid stabilization, and transfer genes of the IncX3 plasmid backbone (green) and hypothetical proteins (light blue). The IncX3 plasmid backbone is marked in purple. GC content is represented by the inner green line and AT content by the inner blue line.




FIGURE 2 | Genetic environment of *bla*_{OXA-484}, *bla*_{OXA-181}, and *bla*_{OXA-232} within pOXA-484_EC-JS316, pOXA-181_EC-2800, and pOXA-232_KP-4814. Colored arrows indicate insertion elements (yellow), fragmented genes (gray), antibiotic resistance genes (red) and genes of the plasmid backbone (green). Shaded regions between the plasmids share >99% nucleotide sequence identity.

Sequence Analysis of pOXA-484

The plasmid pOXA-484 consisted of a conserved IncX3 backbone region of ~31 kb length encoding 21 genes for plasmid replication, mobilization and stabilization as well as 19 hypothetical proteins (Figure 1). The second ~20 kb region of the plasmid contained the two antibiotic resistance genes *bla*_{OXA-484} and *qnrS1* inside a mosaic region of 12 insertion sequences, 6 genes coding for hypothetical proteins, and 4 disrupted genes

(Figure 1). Two IS26 sequences form a functional composite transposon including the gene *bla*_{OXA-484} (Qin et al., 2018). The *bla*_{OXA-484} was flanked by a truncated *ISEcp1* element and two AT-rich direct target repeats (ATCTT), which has been associated with mobilization of *bla*_{OXA-181} from Cole2 to IncX3 plasmids (Liu et al., 2015).

For sequence comparison of pOXA-484 to plasmids encoding related OXA-48-like variants, we conducted whole genome




TABLE 3 | MICs of *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ transformants (Tf) harboring pTOPO plasmids encoding *bla*_{OXA-484}, *bla*_{OXA-232}, *bla*_{OXA-244}, *bla*_{OXA-181}, and *bla*_{OXA-48}.

β-Lactam ^{a,b,c}	MIC (mg/L)											
	J53	Tf pTOPO	Tf pTOPO	Tf pTOPO	Tf pTOPO	Tf pTOPO	PRZ	Tf pTOPO	Tf pTOPO	Tf pTOPO	Tf pTOPO	Tf pTOPO
		OXA-484 J53	OXA-232 J53	OXA-244 J53	OXA-181 J53	OXA-48 J53		OXA-484 PRZ	OXA-232 PRZ	OXA-244 PRZ	OXA-181 PRZ	OXA-48 PRZ
Amoxicillin+CLA	2	>256	>256	>256	>256	>256	2	>256	>256	>256	>256	>256
Ampicillin+SUL	2	>256	>256	>256	>256	>256	8	>256	>256	>256	>256	>256
Piperacillin+TAZ	1	>256	>256	>256	>256	>256	8	>256	>256	>256	>256	>256
Ticarcillin+CLA	4	>256	>256	>256	>256	>256	16	>256	>256	>256	>256	>256
Cefuroxime	4	32	32	16	32	32	4	16	16	8	16	16
Cefotaxime	0.06	1	1	1	1	2	0.06	1	1	0.5	1	1
Ceftazidime	0.06	0.5	0.5	0.5	0.5	0.5	0.03	0.5	0.5	0.5	0.5	0.5
Temocillin	4	128	128	128	>1,024	>1,024	2	512	512	512	>1,024	>1,024
Ertapenem	0.03	2	2	1	2	4	0.01	2	2	2	2	4
Imipenem	0.25	2	2	1	2	4	0.12	1	1	1	2	4
Meropenem	0.03	1	1	0.5	1	2	0.03	1	1	1	2	2
Aztreonam	0.03	0.5	0.5	0.25	0.25	0.5	0.01	0.25	0.12	0.06	0.12	0.12

^aCLA, clavulanic acid (2 mg/L). ^bSUL, sulbactam (4 mg/L). ^cTAZ, tazobactam (4 mg/L). MICs of Tf with at least 2-fold differences compared to OXA-484 are highlighted in bold.

sequencing (WGS) using short- and long-read sequencing of the clinical isolates *E. coli* 2800 (EC-2800) and *K. pneumoniae* 4814 (KP-4814). EC-2800 carried *bla*_{OXA-181} on an IncX3 plasmid of 51.5 kb and KP-4814 *bla*_{OXA-232} on a ColE plasmid of 6.1 kb. Both plasmids share high sequence similarity of >99.9% with previously described plasmids encoding *bla*_{OXA-181} and *bla*_{OXA-232} (Qin et al., 2018; Li et al., 2019).

Comparison of pOXA-484 to the nucleotide sequence of pOXA-181 from EC-2800 revealed a sequence identity of >99.9% with only four bases difference (Figure 2). Sequence comparison of pOXA-484 to the NCBI database revealed numerous IncX3 plasmids harboring *bla*_{OXA-181} from different *Enterobacteriales*

with a nucleotide sequence similarity >99.9% (accession no. KX523903.1, MG893567.1, and MK412916.1) indicating a common origin (Skalova et al., 2017; Qin et al., 2018; Mouftah et al., 2019). The sequence comparison of pOXA-484 to pOXA-232 from isolate KP-4814 revealed a fragment of only 2,964 bp shared between the two plasmids with >99.9% sequence identity (Figure 2).

Horizontal Gene Transfer of pOXA-484

To evaluate the HGT efficiency of pOXA-484, we compared the transconjugation frequencies of plasmid pOXA-484 carrying *bla*_{OXA-484} to the frequencies of plasmids encoding *bla*_{OXA-48},

*bla*_{OXA-181}, and *bla*_{OXA-232}, using the recipient strains *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ. Four representative clinical isolates carrying *bla*_{OXA-48} or *bla*_{OXA-181} were chosen from a collection of clinical isolates based on species (*E. coli* and *K. pneumoniae*) and different STs. Since OXA-232 is rarely found in *E. coli*, only two clinical *K. pneumoniae* isolates harboring *bla*_{OXA-232} were selected (Table 1 and Supplementary Table 4).

Transconjugation of plasmids harboring *bla*_{OXA-48}, *bla*_{OXA-181}, and *bla*_{OXA-484} from all clinical isolates to *E. coli* J53 and *K. quasipneumoniae* subsp. *quasipneumoniae* PRZ was observed, thereby showing intraspecies and intergenus HGT (Figure 3). Transconjugation of plasmid pOXA-484 to J53 and PRZ occurred at mean frequencies of 1.4×10^{-7} and 2.1×10^{-6} , respectively (Figure 3). Similar frequencies were determined for *bla*_{OXA-181}, ranging from 2.7×10^{-7} to 3.6×10^{-5} for J53 and 5.2×10^{-8} to 6.7×10^{-7} for PRZ. In contrast, transconjugation frequencies of *bla*_{OXA-48} from *E. coli* and *K. pneumoniae* donors to J53 and PRZ were significantly higher, ranging from 8.6×10^{-5} to 8.0×10^{-4} for J53 and 1.3×10^{-5} to 3.6×10^{-5} for PRZ ($P < 0.001$).

E. coli J53 Tc were further investigated by long-read genome sequencing and disk diffusion which verified the presence of the respective *bla*_{OXA-48-like} as well as *qnrS1* in *bla*_{OXA-181} and the *bla*_{OXA-484} Tc, respectively, as anticipated (Supplementary Tables 5, 6). For *bla*_{OXA-181} and *bla*_{OXA-484} Tc only the *bla*_{OXA-48-like} harboring IncX3 plasmids were transferred. Notably, in three out of four *bla*_{OXA-48} Tc additional plasmids were identified: a 61.1 kb IncFII plasmid in Tc-EC-2700, a 5.2 kb Col440II plasmid in Tc-EC-1402 and a 3.5 kb Col(pHAD28) as well as a 10.7 kb Col440II plasmid in Tc-EC-1673. However, these plasmids did not harbor any antibiotic resistance genes nor was an impact on HGT frequency or antibiotic resistance phenotype observed when comparing all *bla*_{OXA-48} Tc to each other (Figure 3 and Supplementary Table 6).

Beta-Lactam Resistance Mediated by OXA-484

To analyze the resistance phenotype caused by OXA-484, we evaluated MICs of Tc or Tf harboring the natural plasmids as well as Tf carrying pTOPO expression vectors encoding the genes for OXA-484, OXA-181, OXA-232, OXA-244, and OXA-48, respectively. Since *bla*_{OXA-244} is generally localized on the chromosome, only MICs of Tf carrying pTOPO expression vector encoding *bla*_{OXA-244} were analyzed.

The presence of pOXA-48-like plasmids resulted in increased MICs for penicillins and carbapenems compared to J53 and PRZ parental strains, whereas only minor differences were observed for cephalosporins and aztreonam (Table 2). Carbapenem MICs of pOXA-484 were either unchanged or slightly lower compared to other OXA-48 variants. In contrast, differences in MICs of at least 2-fold between the OXA-48-like variants were detected for the antibiotics piperacillin ± tazobactam and temocillin. Tc with plasmids encoding *bla*_{OXA-48} and *bla*_{OXA-181} presented higher MICs for temocillin compared to

recipients harboring *bla*_{OXA-484} and *bla*_{OXA-232} but lower MICs for piperacillin ± tazobactam in case of J53.

In J53 and PRZ Tf carrying the high copy pTOPO expression vector, the lower MICs for temocillin caused by OXA-484 and OXA-232 compared to OXA-181 and OXA-48 were also observed. Transformants carrying TOPO encoding *bla*_{OXA-244} showed almost identical MICs for all antibiotics tested compared to Tf pTOPO OXA-484. Furthermore, pTOPO OXA-48 Tf displayed higher carbapenem MICs compared to the other Tf.

Taken together, the β-lactam resistance patterns of Tc and Tf harboring *bla*_{OXA-484} revealed similar MICs to OXA-232 and OXA-244. Compared to OXA-181 and OXA-48, piperacillin ± tazobactam MICs were higher for Tc pOXA-484 J53, whereas temocillin MICs were lower for both Tc and Tf harboring either the natural plasmid or pTOPO expression vector.

DISCUSSION

This study is the first characterization of the carbapenemase OXA-484, a variant of the growing family of OXA-48-like enzymes. The dissemination of OXA-48-like carbapenemases has been attributed to highly efficient HGT to different species, low fitness burden of plasmids encoding *bla*_{OXA-48-like}, association with epidemiological successful lineages and difficult to detect carbapenemase phenotypes (Hamprecht et al., 2019; Pitout et al., 2019). The plasmid pOXA-484 from isolate EC-JS316 was transferable to *E. coli* and *K. quasipneumoniae* subsp. *quasipneumoniae*, revealing efficient intraspecies and intergenus transfer (Figure 3). The transconjugation frequencies of this plasmid are very similar to those of the widely distributed IncX3 plasmid harboring *bla*_{OXA-181}. Sequence analysis of pOXA-484 revealed the close relationship to IncX3 plasmids containing *bla*_{OXA-181} suggesting that pOXA-484 might have evolved from pOXA-181 (Figure 2). Sequence analysis of IncX3 plasmids harboring *bla*_{OXA-181} has revealed the potential mobilization of *bla*_{OXA-181} by action of an *ISEcp1* from ColE-plasmids to IncX3 plasmids (Liu et al., 2015). The highly similar sequences between the IncX3 plasmids harboring *bla*_{OXA-484} and *bla*_{OXA-181} including the *ISEcp1* elements and two AT-rich direct target repeats bracketing *bla*_{OXA-484} suggest the same mechanism of mobilization for *bla*_{OXA-484}. The spread of OXA-181 and OXA-232 has additionally been associated with specific high-risk clones like ST101, ST307 and ST15 for *K. pneumoniae* and ST38 and ST410 for *E. coli* (Cubero et al., 2015; Li et al., 2019; Pitout et al., 2019; Chudejova et al., 2021). Notably, the *E. coli* isolate JS316 belongs to the high-risk ST410, which has been identified as a worldwide distributed extraintestinal pathogenic *E. coli* lineage causing nosocomial outbreaks (Roer et al., 2018; Patiño-Navarrete et al., 2020).

The β-lactam resistance pattern caused by OXA-484 was comparable to the resistance phenotypes mediated by OXA-232 and OXA-244. However, carbapenem and temocillin MICs in OXA-484 expressing *E. coli* and *K. quasipneumoniae* subsp. *quasipneumoniae* were lower compared to OXA-48 and OXA-181 producers (Tables 2, 3). In a recent study,

analyses of kinetic parameters and structural models of OXA-181 variants with mutations at amino acid position 214 in the β 5- β 6 loop revealed the critical impact of this amino acid on β -lactamase activity (**Supplementary Figure 1**) (Oueslati et al., 2020). Interestingly, an OXA-181 variant with a R214G mutation resembling the exact amino acid sequence of OXA-484 was included in this study. Enzyme kinetics of OXA-181 214G (or OXA-484) revealed low catalytic efficiencies for temocillin [$0.15 \pm 0.07 k_{cat}/K_m$ ($\text{mM}^{-1}/\text{s}^{-1}$)] and imipenem [$20 \pm 6.9 k_{cat}/K_m$ ($\text{mM}^{-1}/\text{s}^{-1}$)], which are similar to OXA-232 and lower than for OXA-181 and OXA-48 (Oueslati et al., 2014, 2020). These results are in line with our antimicrobial susceptibility results (**Tables 2, 3**).

Substitution of arginine at amino acid 214 in OXA-48 to glycine in OXA-244 (R214G), which is also found in OXA-484, led to a reduced hydrolysis activity and MICs for temocillin and carbapenems (Hoyos-Mallecot et al., 2017). Reduced temocillin hydrolysis will most likely affect the sensitivity of temocillin-based screening plates and tests (Hopkins et al., 2019). Recently, increasing numbers of isolates expressing OXA-244 in the European Union have been linked with difficult detection because of only moderately elevated MICs for carbapenems of these isolates (European Centre for Disease Prevention and Control, 2020; Kremer et al., 2020). Likewise, the isolate EC-JS316 harboring *bla*_{OXA-484} did not grow on selective agar plates used for detection of CPE, suggesting that OXA-484 might be more easily missed and hence be more prevalent than currently known.

IncX3 plasmids have no significant negative effect on fitness of *Enterobacteriales* isolates, which has also been shown for highly successful plasmids of the IncL group harboring *bla*_{OXA-48} and which is a predictor for efficient dissemination (Kassis-Chikhani et al., 2013; Hamprecht et al., 2019). These properties of the IncX3 plasmids might promote the further distribution of OXA-484, as already shown for other carbapenemases like NDM or KPC as well as CTX-M type ESBLs (Kassis-Chikhani et al., 2013; Wu et al., 2019).

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and

accession number(s) can be found below: <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA644256> and <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA644257>.

ETHICS STATEMENT

All bacterial strains were isolated as part of routine microbiological diagnostics and stored in an anonymized database. According to the Ethics Committee of the Hospital of Johann Wolfgang Goethe-University, Frankfurt am Main, no informed consent or ethical approval of the study is necessary.

AUTHOR CONTRIBUTIONS

JSo and SG designed the study, analyzed the data, and drafted the manuscript. JSo, FK, KG, FW, MT, and SR-C performed the experiments. JSo carried out the sequencing and bioinformatic analyses. JSa, AH, and VK edited the manuscript. All authors reviewed the manuscript.

FUNDING

This study was supported by a scholarship of the Frankfurter Promotionsförderung (FPF) of the Faculty of Medicine of the Goethe University, Frankfurt am Main, Germany to JSo.

ACKNOWLEDGMENTS

We thank the team of curators of the Institute Pasteur MLST and whole genome MLST databases for curating the data and making them publicly available. We are indebted to Tobias Herther for outstanding technical assistance.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2021.660094/full#supplementary-material>

REFERENCES

- Baeza, L. L., Pfennigwerth, N., Greissl, C., Göttig, S., Saleh, A., Stelzer, Y., et al. (2019). Comparison of five methods for detection of carbapenemases in *Enterobacteriales* with proposal of a new algorithm. *Clin. Microbiol. Infect.* 25, 1286.e9–1286.e15. doi: 10.1016/j.cmi.2019.03.003
- Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120. doi: 10.1093/bioinformatics/btu170
- Cantón, R., Akóva, M., Carmeli, Y., Giske, C. G., Glupczynski, Y., Gniadkowski, M., et al. (2012). Rapid evolution and spread of carbapenemases among *Enterobacteriaceae* in Europe. *Clin. Microbiol. Infect.* 18, 413–431. doi: 10.1111/j.1469-0691.2012.03821.x
- Carattoli, A., Zankari, E., García-Fernández, A., Larsen, M. V., Lund, O., Villa, L., et al. (2014). In silico detection and typing of plasmids using plasmidfinder and plasmid multilocus sequence typing. *Antimicrob. Agents Chemother.* 58, 3895–3903. doi: 10.1128/AAC.02412-14
- Choi, K.-H. H., Kumar, A., and Schweizer, H. P. (2006). A 10-min method for preparation of highly electrocompetent *Pseudomonas aeruginosa* cells: application for DNA fragment transfer between chromosomes and plasmid transformation. *J. Microbiol. Methods* 64, 391–397. doi: 10.1016/j.mimet.2005.06.001
- Chudejova, K., Kraftova, L., Mattioni Marchetti, V., Hrabak, J., Papagiannitsis, C. C., and Bitar, I. (2021). Genetic plurality of OXA/NDM-encoding features characterized from *Enterobacteriales* recovered from Czech Hospitals. *Front. Microbiol.* 12:641415. doi: 10.3389/fmicb.2021.641415
- Cubero, M., Cuervo, G., Dominguez, M. Á., Tubau, F., Martí, S., Sevillano, E., et al. (2015). Carbapenem-resistant and carbapenem-susceptible isogenic isolates of *Klebsiella pneumoniae* ST101 causing infection in a tertiary hospital. *BMC Microbiol.* 15:177. doi: 10.1186/s12866-015-0510-9

- de Coster, W., D'Hert, S., Schultz, D. T., Cruts, M., and van Broeckhoven, C. (2018). NanoPack: visualizing and processing long-read sequencing data. *Bioinformatics* 34, 2666–2669. doi: 10.1093/bioinformatics/bty149
- European Centre for Disease Prevention and Control (2020). *Increase in OXA-244-Producing Escherichia coli in the European Union/European Economic Area and the UK since 2013*. Stockholm: ECDC.
- Feldgarden, M., Brover, V., Haft, D. H., Prasad, A. B., Slotta, D. J., Tolstoy, I., et al. (2019). Validating the AMRFINDER tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates. *Antimicrob. Agents Chemother.* 63:e00483-19. doi: 10.1128/AAC.00483-19
- Findlay, J., Hopkins, K. L., Loy, R., Doumith, M., Meunier, D., Hill, R., et al. (2017). OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014. *J. Antimicrob. Chemother.* 72, 1340–1349. doi: 10.1093/jac/dkx012
- Göttig, S., Gruber, T. M., Stecher, B., Wichelhaus, T. A., and Kempf, V. A. J. (2015). In vivo horizontal gene transfer of the carbapenemase OXA-48 during a nosocomial outbreak. *Clin. Infect. Dis.* 60, 1808–1815. doi: 10.1093/cid/civ191
- Göttig, S., Walker, S. V., Saleh, A., Koroska, F., Sommer, J., Stelzer, Y., et al. (2020). Comparison of nine different selective agars for the detection of carbapenemase-producing Enterobacterales (CPE). *Eur. J. Clin. Microbiol. Infect. Dis.* 39, 923–927. doi: 10.1007/s10096-019-03786-7
- Gruber, T. M., Göttig, S., Mark, L., Christ, S., Kempf, V. A. J., Wichelhaus, T. A., et al. (2014). Pathogenicity of pan-drug-resistant *Serratia marcescens* harbouring bla_{NDM-1}. *J. Antimicrob. Chemother.* 70, 1026–1030. doi: 10.1093/jac/dku482
- Hamprecht, A., Sommer, J., Willmann, M., Brender, C., Stelzer, Y., Krause, F. F., et al. (2019). Pathogenicity of clinical OXA-48 isolates and impact of the OXA-48 IncL plasmid on virulence and bacterial fitness. *Front. Microbiol.* 10:2509. doi: 10.3389/fmicb.2019.02509
- Hopkins, K. L., Meunier, D., Mustafa, N., Pike, R., and Woodford, N. (2019). Evaluation of temocillin and meropenem MICs as diagnostic markers for OXA-48-like carbapenemases. *J. Antimicrob. Chemother.* 74, 3641–3643. doi: 10.1093/jac/dkz383
- Hoyos-Mallecot, Y., Naas, T., Bonnin, R. A., Patino, R., Glaser, P., Fortineau, N., et al. (2017). OXA-244-producing *Escherichia coli* Isolates, a challenge for clinical microbiology laboratories. *Antimicrob. Agents Chemother.* 61:e00818-17. doi: 10.1128/AAC.00818-17
- Kassis-Chikhani, N., Frangeul, L., Drieux, L., Sengelin, C., Jarlier, V., Brisse, S., et al. (2013). Complete nucleotide sequence of the first KPC-2- and SHV-12-encoding IncX plasmid, pKPS90, from *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 57, 618–620. doi: 10.1128/AAC.01712-12
- Katoh, K., and Standley, D. M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol. Biol. Evol.* 30, 772–780. doi: 10.1093/molbev/mst010
- Kremer, K., Kramer, R., Neumann, B., Haller, S., Pfennigwerth, N., Werner, G., et al. (2020). Rapid spread of OXA-244-producing *Escherichia coli* ST38 in Germany: insights from an integrated molecular surveillance approach; 2017 to January 2020. *Eurosurveillance* 25:2000923. doi: 10.2807/1560-7917.ES.2020.25.25.2000923
- Li, X., Ma, W., Qin, Q., Liu, S., Ye, L., Yang, J., et al. (2019). Nosocomial spread of OXA-232-producing *Klebsiella pneumoniae* ST15 in a teaching hospital, Shanghai, China. *BMC Microbiol.* 19:235. doi: 10.1186/s12866-019-1609-1
- Liu, Y., Feng, Y., Wu, W., Xie, Y., Wang, X., Zhang, X., et al. (2015). First report of OXA-181-producing *Escherichia coli* in China and characterization of the isolate using whole-genome sequencing. *Antimicrob. Agents Chemother.* 59, 5022–5025. doi: 10.1128/AAC.00442-15
- Mouftah, S. F., Pál, T., Darwish, D., Ghazawi, A., Villa, L., Carattoli, A., et al. (2019). Epidemic inc₃ plasmids spreading carbapenemase genes in the united arab emirates and worldwide. *Infect. Drug Resist.* 12, 1729–1742. doi: 10.2147/IDR.S210554
- Naas, T., Oueslati, S., Bonnin, R. A., Dabos, M. L., Zavala, A., Dortet, L., et al. (2017). Beta-lactamase database (BLDB)—structure and function. *J. Enzyme Inhib. Med. Chem.* 32, 917–919. doi: 10.1080/14756366.2017.1344235
- Oueslati, S., Nordmann, P., and Poirel, L. (2014). Heterogeneous hydrolytic features for OXA-48-like β -lactamases. *J. Antimicrob. Chemother.* 70, 1059–1063. doi: 10.1093/jac/dku524
- Oueslati, S., Retailliau, P., Marchini, L., Berthault, C., Dortet, L., Bonnin, R. A., et al. (2020). Role of arginine 214 in the substrate specificity of OXA-48. *Antimicrob. Agents Chemother.* 64:e02329-19. doi: 10.1128/AAC.02329-19
- Patiño-Navarrete, R., Rosinski-Chupin, I., Cabanel, N., Gauthier, L., Takissian, J., Madec, J. Y., et al. (2020). Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing *Escherichia coli*. *Genome Med.* 12:10. doi: 10.1186/s13073-019-0699-6
- Pitout, J. D. D., Peirano, G., Kock, M. M., Strydom, K.-A. A., and Matsumura, Y. (2019). The global ascendancy of OXA-48-type carbapenemases. *Clin. Microbiol. Rev.* 33:e00102-19. doi: 10.1128/CMR.00102-19
- Poirel, L., Bonnin, R. A., and Nordmann, P. (2012). Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. *Antimicrob. Agents Chemother.* 56, 559–562. doi: 10.1128/AAC.05289-11
- Potron, A., Nordmann, P., Lafeuille, E., Al Maskari, Z., Al Rashdi, F., and Poirel, L. (2011). Characterization of OXA-181, a carbapenem-hydrolyzing class D beta-lactamase from *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 55, 4896–4899. doi: 10.1128/AAC.00481-11
- Potron, A., Rondinaud, E., Poirel, L., Belmonte, O., Boyer, S., Camiade, S., et al. (2013). Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β -lactamase from *Enterobacteriaceae*. *Int. J. Antimicrob. Agents* 41, 325–329. doi: 10.1016/j.ijantimicag.2012.11.007
- Qin, S., Cheng, J., Wang, P., Feng, X., and Liu, H. M. (2018). Early emergence of OXA-181-producing *Escherichia coli* ST410 in China. *J. Glob. Antimicrob. Resist.* 15, 215–218. doi: 10.1016/j.jgar.2018.06.017
- Roer, L., Overballe-Petersen, S., Hansen, F., Schønning, K., Wang, M., Røder, B. L., et al. (2018). *Escherichia coli* sequence type 410 is causing new international high-risk clones. *mSphere* 3:e00337-18. doi: 10.1128/msphere.00337-18
- Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069. doi: 10.1093/bioinformatics/btu153
- Siguier, P., Perochon, J., Lestrade, L., Mahillon, J., and Chandler, M. (2006). ISfinder: the reference centre for bacterial insertion sequences. *Nucleic Acids Res.* 34, D32–D36. doi: 10.1093/nar/gkj014
- Skalova, A., Chudejova, K., Rotova, V., Medvecký, M., Studentova, V., Chudackova, E., et al. (2017). Molecular characterization of OXA-48-like-producing *Enterobacteriaceae* in the Czech Republic and evidence for horizontal transfer of pOXA-48-like plasmids. *Antimicrob. Agents Chemother.* 61:e01889-16. doi: 10.1128/AAC.01889-16
- Wick, R. R., Judd, L. M., Gorrie, C. L., and Holt, K. E. (2017). Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput. Biol.* 13:e1005595. doi: 10.1371/journal.pcbi.1005595
- Wu, W., Feng, Y., Tang, G., Qiao, F., McNally, A., and Zong, Z. (2019). NDM metallo- β -lactamases and their bacterial producers in health care settings. *Clin. Microbiol. Rev.* 32:e00115-18. doi: 10.1128/CMR.00115-18

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Sommer, Gerbracht, Krause, Wild, Tietgen, Riedel-Christ, Sattler, Hamprecht, Kempf and Göttig. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.